The leading brain imaging analysis software. One powerful diagnostic tool available for multiple modalities and clinical applications.
The Integrated Solution for FDG, Amyloid, SPECT, DaTscan and Epilepsy.
Non-invasive analysis to determine the likelihood that TLE patients will be seizure-free post surgery.
An effective way to monitor disease progression
Integrated analysis to assist
with quantified comparisons of Ioflupane I-123 studies
Integrated analysis specifically designed for Amyloid scans
NeuroQ™, a streamlined, single platform supports the most relevant functional imaging modalities, increasing accuracy in differential diagnosis.
NeuroQ™ is one of the most widely used quantitative tools for differential diagnosis of dementia.
More than 30% of patients with dementia are misdiagnosed. Using FDG-PET in the diagnosis of dementia increases the accuracy of the diagnosis to approximately 90%.
NeuroQ goes beyond the visual read and provides valuable non-subjective diagnostic information. Metabolic levels in more than 240 pre-defined regions of the brain are rapidly compared to those in the normal database and quantified to show the degree of abnormality and statistical significance of the findings.
Daniel Silverman, M.D. PhD, head of Neuronuclear Imaging section, David Geffen School of Medicine at UCLA said "For patients whose clinical work-up has not led to a definitive diagnosis, brain PET is currently our single best tool to differentiate dementias, especially in the early stages of the disease. Adding quantitative analysis to PET can further improve the ability to diagnose the cause of the dementia."
What is NeuroQ? An introduction from its developer, Daniel Silverman, MD, PhD, head of Neuronuclear Imaging section, David Geffen School of Medicine at UCLA.
©2022 SYNTERMED INC. - ALL RIGHTS RESERVED. | FOR PERMISSION, EMAIL